Cellanome

Cellanome

Automated platform for live single-cell assays

Cell Culture Technician

Full-Time
$30 - $35/hr

+ Stock options

Mid
Bachelor's, Associate's
Foster City, CA, USA
In Person

About the job

Requirements
  • A minimum of 2-4 years of relevant cell handling experience.
  • Proven mastery of aseptic technique.
  • Experience working within a Biosafety Level 2 environment.
  • Proficiency with inverted microscopes, hemocytometers or automated cell counters, and cryostorage systems.
  • Ability to comply with personal protective equipment requirements.
  • Strong organizational habits and documentation practices, and the ability to work independently in a fast-paced environment.
Responsibilities
  • Routinely passage, feed, bank, and thaw mammalian cell lines, including primary cells or human-derived lines.
  • Monitor cell growth, confluence, and morphology daily.
  • Provide cells and medium to other lab members.
  • Enforce laboratory safety protocols in accordance with institutional and federal guidelines.
  • Ensure proper usage of personal protective equipment.
  • Safely treat and dispose of liquid and solid biohazardous waste according to standard protocols, including chemical bleaching, autoclaving, and sharps disposal.
  • Perform routine maintenance, deep cleaning, and calibration tracking for Class II Biosafety Cabinets, CO₂ incubators, centrifuges, and water baths.
  • Coordinate annual professional equipment certifications.
  • Conduct routine testing for mycoplasma, sterility, and cross-contamination.
  • Maintain records of cell line passages, batch histories, and repository logs.
  • Prepare standard cell culture media, buffers, and reagents under sterile conditions.
  • Manage laboratory inventory and track stock levels of plastics, personal protective equipment, and reagents.
Desired Qualifications
  • Hands-on experience in a dedicated cell culture environment, academic or industry.
  • An Associate or Bachelor's degree.

About the company

Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.

Company Size

51-200

Company Stage

Series C

Total Funding

$276.9M

Headquarters

Foster City, California

Founded

2020

Get referred to Cellanome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cellanome updated its website August 2026, showing active product and content momentum.
  • AGBT March 2026 coverage and April 2026 posters show expanding scientific validation.
  • Psomagen added R3200 on March 26, 2026, expanding external distribution and credibility.

What critics are saying

  • The June 22, 2026 $75.9 million Form D signals continued capital dependence.
  • Psomagen's March 26, 2026 launch validates Cellanome while commoditizing its core workflow.
  • Any R3200 commercialization stumble kills a hardware-plus-consumables model before recurring revenue matures.

What makes Cellanome unique

  • R3200 pairs live-cell imaging with single-cell transcriptomics from the same cells.
  • CellCage technology keeps cells viable, trackable, and measurable over time.
  • Omead Ostadan’s December 2025 debut signaled a platform-first strategy across multi-omics biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Stock Options

401(k) Retirement Plan

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

↑ 2%

1 year growth

↑ 32%

2 year growth

↑ 5%
U.S. Securities and Exchange Commission
Jul 17th, 2026
EDGAR Filing Documents for 0000905148-26-003005

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659

Intelligence360 News
Jul 17th, 2026
Cellanome files to raise $75.9M for live-cell imaging and single-cell transcriptomics platform

Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.

The Business Journals
Jan 30th, 2024
Peninsula startup with Illumina roots lands $150 million to peer deeper into cells

A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.

The Business Journals
Dec 8th, 2021
Former Illumina execs, Grail co-founder raise $21M for biotech startup

Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.